Work

The Promise and Perils of Diversity Action Plans for Clinical Trials

Year: 2024

Type: article

Abstract: This Viewpoint discusses the US Food and Drug Administration’s authority to require drug and device sponsors to submit diversity action plans and policy gaps that limit the organization’s ability to achieve demographic representation in clinical trials.

Source: JAMA

DOI: 10.1001/jama.2024.18225

Authors: Tanvee Varma, Barbara E. Bierer, Andrew Hantel

Institutions: Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute

Language: English

Topic: Ethics in Clinical Research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Reduced inequalities

Open Access status: green